Epidaza (chidamide) / Chipscreen |
ChiCTR-OPC-16008628: Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma |
|
|
| Recruiting | 4 | 20 | | Chidamide with Rituximab | Qilu Hospital, Shandong University; Level of the institution:, none | Germinal center subtype of Diffuse Large B Cell Lymphoma | | | | |
ChiCTR1800015871: A clinical study of chidamide with FLAG (fludarabine+cytarabine+G-CSF) in the treatment of relapsed /refractory /first cycle induced non-remission acute myeloid leukemia |
|
|
| Recruiting | 4 | 10 | | Chidamide | Anhui Provincial Hospital; Anhui Provincial Hospital, chipscreen | Acute myeloid leukemia | | | | |
ChiCTR-OPC-16010301: Efficacy and safety of chidamide, bortezomib and dexamethasone combination in transplant-ineligible patients with relapsed/refractory multiple myeloma: a phase 2, single center, single arm study |
|
|
| Recruiting | 4 | 80 | | bortezomib, chidamide and dexamethasone combination protocol | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Project funding | Multiple Myeloma | | | | |
ChiCTR-OIC-17011303: A prospective, open-lable, single-arm, muti-center study evaluating the efficacy and saftety of chidamide in combination with CHOP in patients with newly diagnosed peripheral T-cell lymphoma (PTCL) |
|
|
| Recruiting | 4 | 39 | | Chidamide+CHOP | the First Affiliated Hospital of Soochow University; the First Affiliated Hospital of Soochow University, none | Peripheral T-cell lymphoma | | | | |
NCT04490590: A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma |
|
|
| Recruiting | 4 | 30 | RoW | Chidamide+ Etoposide | Mingzhi Zhang | NK/T-Cell Lymphoma | 10/20 | 10/21 | | |
ChiCTR2000037232: Azacitidine plus chidamide in patients with T/NK-cell lymphoma : a prospective, multicentre, phase 2 trial |
|
|
| Recruiting | 4 | 30 | | Azacitidine plus chidamide | Anhui Provincial Cancer Hospital; Anhui Provincial Cance Hospital, Self-collected | T/NK-cell lymphoma | | | | |
ChiCTR2100048016: A multicenter, prospective real-world study of chidamide combined with fulvestrant in the treatment of advanced breast cancer |
|
|
| Not yet recruiting | 4 | 100 | | Chidamide plus fulvestrant | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Shenzhen Chipscreen Biosciences Co.,Ltd. | Breast cancer | | | | |
NCT05191914: Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors |
|
|
| Not yet recruiting | 4 | 20 | NA | Chidamide+ Fulvestrant | Liaoning Tumor Hospital & Institute | Breast Cancer | 07/22 | 12/22 | | |
ChiCTR2100046678: A clinical trail of chidamide plus exemestane in neoadjuvant therapy for early Hormone receptor-positive breast cancer |
|
|
| Recruiting | 4 | 20 | | chidamide plus exemestane | Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital, Shenzhen Chipscreen Biosciences Co.,Ltd. | breast cancer | | | | |
ChiCTR2100053788: A prospective, multicenter, single-arm clinical trial of chidamide in combination with exemestane in patients with hormone receptor-positive, HER2-negative advanced breast cancer |
|
|
| Not yet recruiting | 4 | 20 | | chidamide in combination with exemestane | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, The First Affiliated Hospital of University of Science and Technology of China | breast cancer | | | | |
ChiCTR2200061380: A prospective, single-arm, multicenter clinical study of the efficacy and safety of veneclax combined with chidamide in the treatment of adult patients with high-risk myelodysplastic syndrome who have failed demethylating drugs |
|
|
| Not yet recruiting | 4 | 20 | | conventional chemotherapy | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, funding | Myelodysplastic Syndrome | | | | |
ChiCTR2100044282: A single-arm, single-center, observational clinical study of chidamide combined with fulvestrant in the treatment of HR+/HER2- advanced breast cancer that has failed endocrine therapy |
|
|
| Recruiting | 4 | 30 | | Chidamide combined with fulvestrant | Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, self-raised | Breast cancer | | | | |
ChiCTR2200058721: Open-ended prospective clinical trial of skeleton scheme based on epigenetics in combination with DEL chemotherapy in relapsed/refractory children with acute T-lymphocyte leukemia (T-ALL) or T cell lymphoblastic lymphoma (T-NHL) |
|
|
| Not yet recruiting | 4 | 60 | | Chidamide + HMAs + Venetoclax+Dex+VP16+Peg-Asp | Children's Hospital of Soochow University; Children's Hospital of Soochow University, Suzhou government and Children's Hospital of Soochow University | acute T-lymphocyte leukemia or T cell lymphoblastic lymphoma | | | | |
ChiCTR1900025028: Chidamide for maintenance therapy of peripheral T cell lymphoma (PTCL) patients, a multi-center, prospective, randomized, open-label trial |
|
|
| Not yet recruiting | 4 | 273 | | chidamide monotherapy ;N/A | Harbin Institute of Hematology & Oncology; Harbin Institute of Hematology & Oncology, Self-collected | Peripheral T cell lymphoma | | | | |
ChiCTR2100049723: Efficacy of Chidamide plus BVD versus BVD in patients with relapse/refractory MM: a prospective, multicenter, randomized controlled clinical trial |
|
|
| Not yet recruiting | 4 | 120 | | Chidamide plus BVD ;BVD | Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, self-funded | multiple myeloma | | | | |
ChiCTR1800017698: A single arm, open label study for evaluation the effect and saft of Chidamide in the treatment of HBV positive diffuse large B cell lymphoma |
|
|
| Recruiting | 4 | 20 | | maintenance of Chidamide | the First Hospital of Jilin University; The First Hospital of Jilin University, Shenzhen microbiological science and Technology Co, Ltd. | Diffuse large B cell lymphoma | | | | |
ChiCTR2200060408: Maintenance therapy with Chidamide in patients with newly developed peripheral T-cell lymphoma after sequential autologous hematopoietic stem cell transplantation with Chidamide combined with BeMit chemotherapy |
|
|
| Not yet recruiting | 4 | 48 | | Maintenance therapy with Chidamide and BeMit regimen after sequential autologous stem cell transplantation | Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, none | newly developed peripheral T-cell lymphoma | | | | |
ChiCTR2300068673: Efficacy and safety of Zimberelimab combined with Chidamide and etoposide/gemcitabine in the treatment of peripheral T-cell lymphoma |
|
|
| Recruiting | 4 | 20 | | Zimberelimab combined with Chidamide and etoposide/gemcitabine | Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet | Peripheral T-cell lymphoma | | | | |
ChiCTR2300075789: Multicenter single-arm clinical study of Chidamide combined with T/TP regimen in first-line treatment of advanced triple negative breast cancer |
|
|
| Recruiting | 4 | 93 | | Chidamide combined with T/TP regimen | China-Japan Friendship Hospital; China-Japan Friendship Hospital, Beijing Health Promotion Association | triple negative breast cancer | | | | |
| Not yet recruiting | 4 | 78 | | Chidamide + tislelizumab + chemotherapy; Chidamide + cardonilizumab + chemotherapy | Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University, Self-raised | advance gastric carcinoma | | | | |
ChiCTR2400081280: A single arm, multicenter, exploratory clinical study of dalpiciclib combined with chidamide and letrozole in the adjuvant treatment of HR positive and HER2 negative breast cancer |
|
|
| Not yet recruiting | 4 | 30 | | dalpiciclib combined with chidamide and letrozole | An Yang Tumor Hospital; An Yang Tumor Hospital, raise independently | breast cancer | | | | |
ChiCTR2300075418: Clinical study of Mitoxantrone liposome, Azacitidine and Chidamide in the treatment of angioimmunoblastic T-cell lymphoma (AITL) |
|
|
| Recruiting | 4 | 45 | | Mitoxantrone liposome, Azacitidine and Chidamide | Shanxi Cancer Hospital/Cancer Hospital of the Chinese Academy of Medical Sciences, Shanxi Hospital; Shanxi Cancer Hospita, Corporate Sponsorship | Angioimmunoblastic T-cell lymphoma | | | | |
ChiCTR2100042420: Tucidinostat combined with AI versus AI alone for hormone receptor-positive, HER2-negative breast cancer with poor efficacy of neoadjuvant chemotherapy: a phase II, multicenter, prospective, controled study |
|
|
| Recruiting | 4 | 40 | | Tucidinostat combined with AI (±OFS) ;AI alone (±OFS) | The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, self-raised | breasr cancer | | | | |
| Recruiting | 4 | 20 | | Duvelisib and Chidamide in combination with CHOP regimen | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-funded | Angioimmunoblastic T cell lymphoma | | | | |
| Recruiting | 4 | 15 | | Azacitidine and Chidamide in combination with Mitoxantrone Hydrochloride Liposome | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-funded | Angioimmunoblastic T cell lymphoma | | | | |
ChiCTR2300075225: Safety and efficacy of Chidamide combined with chemotherapy in the treatment of newly diagnosed T-cell acute lymphoblastic leukemia in children: a multicenter randomized controlled study |
|
|
| Not yet recruiting | 4 | 160 | | Dexamethasone, vincristine, daunorubicin, asparaginase; Dexamethasone, Vincristine, Daunorubicin, Asparaginase, Cedaramine | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, No | Childhood T-cell acute lymphoblastic leukemia | | | | |
| Not yet recruiting | 3 | 480 | RoW, Europe | Tucidinostat, HBI-8000, Tablet, Concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion nivolumab | HUYABIO International, LLC, HUYABIO International | Metastatic or unresectable melanoma, Skin Cancer, Diseases [C] - Cancer [C04] | | | | |
DEB, NCT04231448: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL |
|
|
| Active, not recruiting | 3 | 423 | RoW | R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo | Chipscreen Biosciences, Ltd. | Diffuse Large B-cell Lymphoma | 07/23 | 03/25 | | |
NCT05075460: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 3 | 107 | RoW | Tucidinostat, Azacitidine combined with CHOP | Peking Union Medical College Hospital | T-cell Lymphoma | 05/24 | 10/24 | | |
RJ-NKTCL-3, NCT06255795: The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma |
|
|
| Not yet recruiting | 3 | 142 | RoW | chidamide, anti-PD1 antibody, and pegaspargase, DDGP | Ruijin Hospital | Extranodal Natural Killer T Cell Lymphoma | 12/26 | 12/28 | | |
NCT06497985: Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients |
|
|
| Not yet recruiting | 3 | 430 | NA | Tucidinostat, Chidamide, Sintilimab, Bevacizumab, Fruquintinib | Chipscreen Biosciences, Ltd. | Colorectal Cancer | 05/28 | 09/28 | | |
NCT04674683: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma |
|
|
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | HBI-8000 in combination with nivolumab, For HBI-8000: tudicdinostat; For nivolumab: OPDIVO®, Placebo in combination with nivolumab, For nivolumab: OPDIVO® | HUYABIO International, LLC., Bristol-Myers Squibb | Unresectable or Metastatic Melanoma, Progressive Brain Metastasis | 12/24 | 10/25 | | |
| Recruiting | 3 | 306 | RoW | Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant | Sichuan University | Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | 12/25 | 12/25 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL |
|
|
| Recruiting | 3 | 104 | RoW | C-BEAM Regimen, BEAM Regimen | The First Affiliated Hospital with Nanjing Medical University | Newly Diagnosed Peripheral T-cell Lymphoma | 02/26 | 02/28 | | |
NCT06122389: SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide | Jiangsu HengRui Medicine Co., Ltd. | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | 05/26 | 07/26 | | |
NCT05678933: AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH |
|
|
| Enrolling by invitation | 3 | 200 | RoW | Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Tianjin Medical University Cancer Institute and Hospital | Peripheral T-cell Lymphoma Targeted Therapy | 12/27 | 12/29 | | |
NCT04668690: Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL |
|
|
| Not yet recruiting | 3 | 190 | RoW | Mitoxantrone Hydrochloride Liposome Injection, HE071, Liposomal Mitoxantrone Hydrochloride Injection, Chidamide | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Peripheral T Cell Lymphoma | 12/27 | 12/28 | | |
NCT05253066: Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer |
|
|
| Not yet recruiting | 2/3 | 130 | NA | Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) | Shengjing Hospital | Breast Neoplasms | 07/22 | 01/25 | | |
| Recruiting | 2/3 | 120 | RoW | Chidamide, HDACi chidamide, Dasatinib, TKI dasatinib | Nanfang Hospital of Southern Medical University | Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell | 08/23 | 08/23 | | |
ChiCTR-TNC-10000811: Phase II Clinical Trial of Chidamide in Patients with Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 51 | | 口服西达本胺每周两次,每次30mg | Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences, Ltd, Chipscreen Biosciences,Ltd. | Peripheral T-cell Lymphoma | | | | |
| Completed | 2 | 82 | | Oral Chidamide 30mg twice weekly | Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences Co., Ltd., Chipscreen Biosciences Co., Ltd. | Cutaneous T-cell lymphoma | | | | |
ChiCTR-IIC-15006786: The combined regimen of Chidamide with Prednisone, Cyclophosphamide, Etoposide, and Methotrexate for Relapsed/ Refractory Peripheral T Cell Lymphoma (PTCL), a multicenter, single arm, open-label phase II clinical trial |
|
|
| Recruiting | 2 | 92 | | Chidamide with Prednisone, Cyclophosphamide, Etoposide, and Methotrexate | Sun Yat-sen University Cancer Center; Level of the institution:, Uncertain at present | Peripheral T Cell Lymphoma | | | | |
ChiCTR-IIR-15007350: Radomized and Controlled Phase II Study and Prognosis Analysis for the Early Stage and High Risk Extranodal Nasal NK/T Cell Lymphoma |
|
|
| Recruiting | 2 | 98 | | Chidamide+radiotherapy+chemotherapy ;radiotherapy+chemotherapy | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing Marathon of Hope Special Found from Cancer Foundation of China | Extranodal nasal NK/T cell lymphoma | | | | |
ChiCTR1800015471: Phase II clinical study of chidamide monotherapy in the treatment of relapsed or refractory extranodal nasal type NK/T cell lymphoma |
|
|
| Not yet recruiting | 2 | 80 | | Chidamide | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Shenzhen Chipscreen Biosciences, Ltd; West China Hospital of Sichuan University | NK/T lymphoma | | | | |
ChiCTR1800017740: A prospective, single-arm evaluating the efficacy and safety of chidamide, CAG and DLI in patients with high risk or relapse hematological malignancies after allogeneic stem cell transplantation |
|
|
| Recruiting | 2 | 30 | | chidamide+CAG+DLI | Chinese People's Liberation Army General Hospital; China PLA General Hospital, patients | acute leukemia or myelodysplastic syndrome | | | | |
NCT03617432: Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients |
|
|
| Recruiting | 2 | 114 | RoW | Chidamide, epidaza, Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone | Peking University, Peking University International Hospital, Shandong Tumor Hospital, Jiangxi Provincial Cancer Hospital | Experimental Tumor | 09/20 | 09/22 | | |
ChiCTR1800015332: Study of Chidamide combined decitabine and etoposide in treating refractory and relapsed adult AML |
|
|
| Recruiting | 2 | 84 | | CDE regimen | Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Chipscreen (Chidamide) | Acute myeloid leukemia | | | | |
NCT03611231: Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma |
|
|
| Not yet recruiting | 2 | 43 | RoW | Chidamide, epidaza | Peking University, Hebei Medical University Fourth Hospital, Peking University International Hospital | Experimental Tumor | 12/20 | 12/22 | | |
NCT03853044: Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 23 | RoW | Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Ruijin Hospital | Angioimmunoblastic T-cell Lymphoma | 06/21 | 12/22 | | |
| Recruiting | 2 | 128 | RoW | Cyclophosphamide, Rituximab, Doxorubicin, Vincristine, Prednisone, Ibrutinib, Lenalidomide, chidamide, decitabine | Ruijin Hospital | Diffuse Large B Cell Lymphoma | 07/21 | 06/23 | | |
| Not yet recruiting | 2 | 51 | NA | chidamide combined with rituximab and high-dose methotrexate | Fudan University | Central Nervous System Lymphoma | 09/21 | 08/23 | | |
ChiCTR1900027562: Clinical study for chidamide combined with bortezomib, dexamethasone and doxorubicin hydrochloride liposome injection in the treatment of relapse/refractory multiple myeloma |
|
|
| Recruiting | 2 | 15 | | Refractory/relapsed multiple myeloma patient group | Peking University People's Hospital; Peking University People's Hospital, Self preparation | Multiple myeloma | | | | |
NCT03245905: Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL |
|
|
| Recruiting | 2 | 100 | RoW | Chidamide, epidaza | Sun Yat-sen University | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) | 12/21 | 12/21 | | |
NCT03629873: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects |
|
|
| Active, not recruiting | 2 | 69 | RoW | Chidamide, Carmustine, Etoposide, Cytarabine, Cyclophosphamide, Autologous hematopoeitic stem cell transplantation | The First Affiliated Hospital with Nanjing Medical University | Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma, Double-hit Lymphoma | 12/21 | 12/21 | | |
ChiCTR2100050169: Chidamide combined with rituximab in the treatment of recurrent / refractory elderly (over 65 years old) diffuse large B-cell lymphoma: a phase II clinical study |
|
|
| Recruiting | 2 | 30 | | Chidamide combined with rituximab | Tianjin Union Medical Center; Tianjin Union Medical Center, self-financing | lymphoma | | | | |
NCT04329130: Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 44 | RoW | Chidamide, Lenalidomide | Sun Yat-sen University | Relapsed or Refractory Peripheral T-cell Lymphoma | 03/22 | 03/25 | | |
| Recruiting | 2 | 26 | RoW | Rituximab, chidamide, lenalidomde | Zhejiang Cancer Hospital | Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 03/22 | 12/22 | | |
ChiCTR2000041542: Phase II study of Chidamide and Tislelizumab in advanced non-small cell lung cancer |
|
|
| Recruiting | 2 | 76 | China | Chidamide+Tislelizumab(±chemotherapy) | The General Hospital of the People's Liberation Army (PLAGH) ; The General Hospital of the People's Liberation Army (PLAGH), scientific research project | Non-small cell lung cancer | | | | |
ChiCTR2000041541: Phase II study of Chidamide and Tislelizumab in advanced Urothelial carcinoma |
|
|
| Recruiting | 2 | 20 | China | Chidamide plus Tislelizumab and chemotherapy | The General Hospital of the People's Liberation Army (PLAGH) ; The General Hospital of the People's Liberation Army (PLAGH), scientific research project | Urothelial carcinoma | | | | |
NCT04831710: Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL |
|
|
| Not yet recruiting | 2 | 83 | RoW | Sintilimab, Tyvyt®, Chidamide, Epidaza | Sun Yat-sen University | Angioimmunoblastic T-cell Lymphoma | 04/22 | 04/23 | | |
NCT04192903: Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 55 | RoW | Chidamide combined with Cisplatin | Fudan University | Triple-negative Breast Cancer | 06/22 | 06/22 | | |
NCT05088226: Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen |
|
|
| Recruiting | 2 | 50 | RoW | Ruxolitinib combined with Chidamide., Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide | Chinese PLA General Hospital | Peripheral Blood Stem Cell Transplantation | 06/22 | 06/23 | | |
RJ-PTCL-2, NCT04480125: Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy |
|
|
| Recruiting | 2 | 28 | RoW | Azacitidine, Chidamide | Ruijin Hospital | Peripheral T-cell Lymphoma | 06/22 | 06/24 | | |
NCT04414969: Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma |
|
|
| Recruiting | 2 | 35 | RoW | Anti-PD-1 antibody+Peg-Asparaginase+Chidamide, Anti-PD-1 antibody;Peg-Asparaginase;Chidamide | Hunan Cancer Hospital | Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder, NK/T-cell Lymphoma of Nasal Cavity | 07/22 | 07/25 | | |
NCT04724239: Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma |
|
|
| Active, not recruiting | 2 | 48 | RoW | Sintilimab, Chidamide, IBI305, Bevacizumab | Sun Yat-sen University | Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer | 07/22 | 12/23 | | |
NCT04514081: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. |
|
|
| Recruiting | 2 | 200 | RoW | Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab | Chinese PLA General Hospital | Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | 08/22 | 08/25 | | |
NCT04562311: Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | Chidamide with tislelizumab | Sun Yat-sen University | Bladder Cancer Stage IV | 09/22 | 09/23 | | |
NCT05076786: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Chidamide, Epidaza, Etoposide + Cisplatin/Carboplatin, EP/EC regimen | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Carcinoma | 10/22 | 10/24 | | |
ChiCTR2000039464: Tlislelizumab Plus Chidamide as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) |
|
|
| Recruiting | 2 | 25 | China | Tislelizumab + Chidamide | Chinese PLA General Hospital ; Chinese PLA General Hospital, Beigene.co.,ltd + chipscreen | Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) | | | | |
NCT05113355: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm |
|
|
| Recruiting | 2 | 23 | RoW | Chidamide, Epidaza, Sintilimab, Tyvyt | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm | 11/22 | 11/24 | | |
NCT04022005: Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL |
|
|
| Completed | 2 | 54 | RoW | Chidamide, Rituximab, Gemcitabine,Oxaliplatin | Sun Yat-sen University | Lymphoma, Large B-Cell, Diffuse | 11/22 | 03/23 | | |
NCT04661943: Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Tucidinostat, Chidamide,CS055,HBI-8000 | oubai | Diffuse Large B-cell Lymphoma | 11/22 | 11/22 | | |
NCT05008666: Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH |
|
|
| Not yet recruiting | 2 | 37 | RoW | Sintilimab, Chidamide, Azacitidine, L-DEP | Sun Yat-sen University | Safety and Efficacy | 11/22 | 04/23 | | |
NCT04296786: Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study |
|
|
| Recruiting | 2 | 52 | RoW | Sintilimab, Chidamide | Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Longfu Hospital, Dongzhimen Hospital, Beijing | Cutaneous T-cell Lymphoma | 12/22 | 12/24 | | |
PCR, NCT05115409: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL |
|
|
| Not yet recruiting | 2 | 27 | NA | Anti-PD-1 Antibody Plus Chidamide and Rituximab | Sun Yat-sen University, Chipscreen Biosciences, Ltd. | Relapsed or Refractory DLBCL | 12/22 | 12/24 | | |
| Recruiting | 2 | 400 | RoW | Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240 | Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group | Carcinoma, Non-Small-Cell Lung | 12/22 | 12/24 | | |
NCT04984018: Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade |
|
|
| Not yet recruiting | 2 | 73 | NA | chidamide + camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 12/23 | | |
NCT05056974: A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs |
|
|
| Completed | 2 | 11 | RoW | UB-421, chidamide | United BioPharma | HIV-1 Infection | 02/23 | 02/23 | | |
NCT05400993: Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC |
|
|
| Recruiting | 2 | 59 | RoW | Chidamide, pharmorubicin, Cyclophosphamide, Docetaxel | Shengjing Hospital | Breast Cancer | 05/23 | 05/24 | | |
ChiCTR2200061074: A multicenter, single-arm, prospective, phase II clinical study of Chidamide combined with chemotherapy in neoadjuvant therapy for HR-positive/HER2-negative breast cancer |
|
|
| Not yet recruiting | 2 | 59 | | Chidamide+pharmorubicin +cyclophosphamide+docetaxel neoadjuvant therapy | Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, Shenzhen Chipscreen Biosciences Co.,Ltd. | Breast cancer | | | | |
NCT05330364: Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia |
|
|
| Recruiting | 2 | 31 | RoW | Chidamide, Cladribine | Ge Zheng | Acute Myeloid Leukemia | 06/23 | 06/23 | | |
NCT05129189: Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression |
|
|
| Recruiting | 2 | 15 | RoW | ASC22 group | Shanghai Public Health Clinical Center | HIV Infections | 07/23 | 07/23 | | |
ChiCTR2000037642: A non-randomized controlled, multicenter phase II clinical trial to evaluate the efficacy and safety of Chidamide combined with Fulvestrant+ /-Sintinlimab treatment of recurrent / metastatic breast cancer patients with HR positive and HER-2 negative breast cancer |
|
|
| Recruiting | 2 | 90 | | Chidamide+Fulvestrant+Sintinlimab ;Chidamide+Fulvestrant ;Fulvestrant | Shandong Cancer Hospital and Institute; Shandong Cancer Hospital and Institute, INNOVENT | Breast cancer | | | | |
NCT05749575: Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. |
|
|
| Recruiting | 2 | 28 | RoW | Chidamide Plus Toripalimab Plus Paclitaxel | Sun Yat-sen University | Breast Cancer | 08/23 | 08/24 | | |
NCT05495100: A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 45 | RoW | Mitoxantrone liposome、Chidamide、Azacitidine | Second Affiliated Hospital, School of Medicine, Zhejiang University, Ningbo No. 1 Hospital, Jinhua Central Hospital, Huizhou Municipal Central Hospital | Peripheral T Cell Lymphoma | 08/23 | 08/24 | | |
NCT04994210: Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab, Tyvyt®, Chidamide, Epidaza | Sun Yat-sen University | Safety and Efficacy | 08/23 | 08/25 | | |
NCT05808582: Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 60 | NA | chidamide,fulvestrant, Regular Visits | The First Affiliated Hospital with Nanjing Medical University | Hormone Receptor-positive Advanced Breast Cancer | 09/23 | 09/24 | | |
ChiCTR2000034888: Chidamide combined with sintilimab for advanced and refactory non-small cell lung cancer: a prospective,multi-cohort, phase Ib/II clinical study |
|
|
| Not yet recruiting | 2 | 60 | | Chidamide combined with sintilimab ;Chidamide combined with sintilimab ;Chidamide combined with sintilimab | National Cancer Center / National Cancer Clinical Medicine Research Center / Cancer Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences; National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, None | Non-small Cell Lung Cancer | | | | |
| Completed | 2 | 30 | RoW | Tucidinostat, Chidamide, Epidaza, Exemestane, Ovarian function suppression | First Affiliated Hospital, Sun Yat-Sen University | Breast Cancer | 10/23 | 10/23 | | |
NCT05519865: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC |
|
|
| Active, not recruiting | 2 | 118 | RoW | Tucidinostat, Chidamide, CS055, Tislelizumab | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 10/24 | 10/24 | | |
NCT05411874: A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP |
|
|
| Not yet recruiting | 2 | 100 | NA | Chidamide, HD-DXM | Shandong University | Thrombocytopenia | 10/23 | 10/24 | | |
NCT05085626: Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | fluzoparib+chidamide, fluzoparib+camrelizumab | Tianjin Medical University Cancer Institute and Hospital | Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer | 10/23 | 12/24 | | |
NCT05438706: A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 70 | RoW | chidamide, camrelizumab, carboplatin, capecitabine | Fudan University | Triple-negative Breast Cancer | 11/23 | 07/24 | | |
NCT06151106: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 33 | RoW | Chidamide combined with Duvillisib | The First Affiliated Hospital of Xiamen University, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital | Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma | 12/24 | 12/25 | | |
NCT06158386: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma |
|
|
| Recruiting | 2 | 33 | RoW | Chidamide combined with Linperlisib | The First Affiliated Hospital of Xiamen University, Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Jieyang People's Hospital, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital | Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | 12/24 | 12/25 | | |
| Recruiting | 2 | 51 | RoW | PD-1 antibody+ HDAC inhibitor, Sintilimab, Chidamide | Fudan University | Peripheral T-cell Lymphoma | 12/23 | 09/25 | | |
NCT04999540: Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 73 | NA | Tucidinostat, Fulvestrant | Guangdong Women and Children Hospital | Breast Cancer | 12/23 | 12/24 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |